Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 12/20 | 0.73 |
| ▸ | EGLN1 | Q9GZT9 | 12/20 | 0.73 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL277668 | 0.88 | EGLN1 (0.85) | VEGFAEGLN1KDM4E | |
| SCHEMBL271963 | 0.88 | EGLN1 (0.85) | VEGFAEGLN1KDM4E | |
| SCHEMBL273696 | 0.88 | EGLN1 (0.85) | VEGFAEGLN1KDM4E | |
| SCHEMBL20763920 | 0.88 | VEGFA (0.57) | VEGFAEGLN1ACHEKDM4EALDH1A1 | |
| SCHEMBL273037 | 0.86 | EGLN1 (0.87) | VEGFAEGLN1KDM4EALDH1A1 | |
| SCHEMBL272075 | 0.86 | VEGFA (0.70) | VEGFAEGLN1ALDH1A1 | |
| SCHEMBL5267745 | 0.85 | VEGFA (0.69) | VEGFAEGLN1ALDH1A1 | |
| SCHEMBL278202 | 0.85 | VEGFA (1.00) | VEGFAEGLN1KDM4EALDH1A1 | |
| SCHEMBL278211 | 0.85 | VEGFA (0.75) | VEGFAEGLN1KDM4EALDH1A1 | |
| SCHEMBL277620 | 0.82 | EGLN1 (0.71) | VEGFAEGLN1ACHEKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2022-06-16 | — | — | US | disclosed |
| EP-3603644-A1 | PROLYL HYDROXYLASE INHIBITORS | Aerpio Therapeutics, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-2952192-B1 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20170298019-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2017-10-19 | — | — | US | disclosed |
| EP-2853265-B1 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9540326-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540326-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-2496082-B1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9278930-B2 | Methods for increasing the stabilization of hypoxia inducible factor-α | AERPIO THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278930-B2 | Methods for increasing the stabilization of hypoxia inducible factor-α | AERPIO THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-8309537-B2 | Compositions and methods for treating colitis | AERPIO THERAPEUTICS INC. (US) | 2012-11-13 | — | — | US | disclosed |
| WO-2011057121-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| WO-2011057115-A1 | PROLYL HYDROXYLASE INHIBITORS | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011057112-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298019-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885CNR1 1896/4885 |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | ALPI, SI, SLC10A2 | VEGFA 4546/4885EGLN1 2861/4885CNR1 879/4885 |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885CNR1 1896/4885 |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | VEGFA 20/4885EGLN1 8/4885CNR1 3038/4885 |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885CNR1 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.